Valhalla, New York 10595


The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).


Inclusion Criteria: - Normal Serum creatinine based on age or creatinine clearance >60 ml/min/1.73 m2 or an equivalent radioisotope glomerular filtration rate (GFR) as determined by the institutional normal range. - Direct bilirubin < 1.5 upper limit of normal (ULN) for age, and SGOT (AST) or SGPT (ALT) <3 x ULN - Shortening fraction >27% by echocardiogram, or - Ejection fraction of >50% by radionuclide angiogram or echocardiogram. - For patients age 1-16 years, Lansky score of ≥60. - For patients > 16 years, Karnofsky score of ≥60. - No prior Hodgkin lymphoma directed therapy is allowed except for emergent mediastinal irradiation (<1000cGy) for superior vena cava (SVC) syndrome. Exclusion Criteria: - Females who are pregnant (positive HCG) or lactating. - Karnofsky <60% or Lansky <60% if less than 16 years of age. - Age ≤1 year or >29.99 years of age.



Primary Contact:

Principal Investigator
Jessica Hochberg, MD
New York Medical College

Jessica Hochberg, MD
Phone: 9145942132

Backup Contact:

Mitchell Cairo, MD
Phone: 9145942150

Location Contact:

Valhalla, New York 10595
United States

Mitchell S Cairo, MD
Phone: 914-594-2150

Site Status: Recruiting

Data Source:

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.